Patients with SPEN mutated CLL had a significantly shorter time-to-first treatment compared to CLL patients with wild type SPEN (2.5 vs. 4.07 years, p = 0.01). This evidence concerns the gene SPEN and B-cell chronic lymphocytic leukemia.